1 The pharmacokinetics and biochemical efficacy of losartan, an orally active nonpeptide angiotensin II (AII) receptor antagonist, were evaluated in healthy male volunteers after single and multiple oral administration. 2 Plasma and urinary concentrations of losartan and its active metabolite, E-3174, were determined by a specific high performance liquid chromatographic (h.p.l.c.) method. 3 Plasma concentrations of losartan were proportional to dose over the range of 25 to 200 mg and the terminal half-lives (t',2,,) ranged from 1.5 to 2.5 h. The mean values of Cmax and AUCO-oo increased in a dose-dependent manner. 4 Plasma concentrations of E-3174 were higher than those of losartan at all dose levels.The values of Cmax and AUCO-°o for E-3174 were approximately 2 and 5-8 times higher than those for losartan, respectively. Also the value of t ' , 2 , , was 2 times longer than that of losartan. 5 After multiple dosing for 7 days, the pharmacokinetics of losartan and E-3174 each did not change significantly between day 1 and day 7. 6 Plasma renin activity (PRA) and plasma concentrations of AII increased markedly at all dose levels. Plasma aldosterone levels were slightly reduced, but a similar decrease was also observed with placebo. 7 No clinically significant adverse reaction was observed in any of the volunteers during either study. Blood counts, routine laboratory tests, urine analyses, and electrocardiograms were also not modified by losartan. 8 Losartan appears to be a potent orally active angiotensin II antagonist with a relatively long duration of action.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.